Explore our comprehensive coverage of melanoma, including scientific research, policy developments, environmental impacts, and solutions for a sustainable future.
Global clinical trials in 2026 reveal that personalized mRNA cancer vaccines can halve the risk of melanoma recurrence and show lasting results in pan...
Read Full Story →
GadgetsModerna and Merck's 5-year follow-up data for the personalized mRNA cancer vaccine intismeran autoge...
BusinessmRNA-4157/V940, a personalized neoantigen therapy developed by Moderna and Merck, has demonstrated a...
Medical ResearchmRNA-4157/V940, a personalized neoantigen therapy developed by Moderna and Merck, has demonstrated a...
HealthModerna and Merck report Phase 3 success for their personalized mRNA neoantigen vaccine in high-risk...
HealthA personalized mRNA vaccine developed by Moderna and Merck has reduced the recurrence of high-risk m...
